Infectious Disease Diagnostics Market Size

The global infectious disease diagnostics market was valued at approximately USD 28.91 billion in 2025 and is projected to reach nearly USD 67.59 billion by 2035, growing at a CAGR of 8.86%.

What is the Infectious Disease Diagnostics Market?

The infectious disease diagnostics market refers to the global industry involved in developing, manufacturing, and commercializing diagnostic technologies used to detect infectious pathogens quickly and accurately. These diagnostics identify bacteria, viruses, fungi, parasites, and other microorganisms responsible for diseases such as influenza, tuberculosis, HIV/AIDS, hepatitis, malaria, dengue, COVID-19, respiratory syncytial virus (RSV), sexually transmitted infections (STIs), and hospital-acquired infections.

The market encompasses:

Molecular diagnostics (PCR, RT-PCR, digital PCR)
Immunodiagnostics
Clinical microbiology
Rapid antigen testing
Point-of-care diagnostics
Next-generation sequencing
Laboratory automation
Companion diagnostic solutions
Multiplex testing platforms

Modern infectious disease diagnostics not only detect pathogens but also identify antimicrobial resistance genes, enabling physicians to prescribe targeted therapies while minimizing unnecessary antibiotic usage.

Get a Free Sample: https://www.cervicornconsulting.com/sample/2787

Why is the Infectious Disease Diagnostics Market Important?

The importance of infectious disease diagnostics continues to grow as healthcare systems shift toward preventive medicine and precision healthcare.

Major reasons include:

Enables early detection before severe symptoms develop
Reduces disease transmission through timely diagnosis
Supports epidemic and pandemic preparedness
Improves treatment selection through pathogen identification
Reduces unnecessary antibiotic prescriptions
Enhances hospital infection control programs
Improves vaccination monitoring
Strengthens national public health surveillance
Supports global disease eradication initiatives
Lowers long-term healthcare costs

Rapid and accurate diagnostics are now considered essential infrastructure for modern healthcare systems because delays in diagnosis can significantly increase mortality, healthcare expenditure, and disease spread.

Infectious Disease Diagnostics Market Growth Factors

The infectious disease diagnostics market is expanding rapidly due to increasing incidences of infectious diseases worldwide, growing antimicrobial resistance, rising demand for rapid point-of-care testing, continuous technological advancements in molecular diagnostics and next-generation sequencing, increasing healthcare expenditure, expansion of diagnostic laboratories, growing awareness regarding early disease detection, rising government investments in public health surveillance, increasing adoption of artificial intelligence in laboratory diagnostics, expanding home-based diagnostic testing, improved reimbursement policies across developed economies, increasing global travel that accelerates disease transmission, growing elderly populations susceptible to infections, rising hospital-acquired infections, favorable regulatory support for innovative diagnostic technologies, stronger pandemic preparedness initiatives, increased collaborations between biotechnology companies and healthcare institutions, and the growing use of multiplex testing platforms capable of detecting multiple pathogens from a single patient sample.

Major Companies Operating in the Infectious Disease Diagnostics Market

Company	Specialization	Key Focus Areas	Notable Features	2025 Revenue*	Estimated Market Share**	Global Presence
3M	Infection prevention and healthcare solutions	Sterilization monitoring, infection prevention, healthcare products	Strong hospital infection prevention portfolio	Approximately US$24.5 Billion	Moderate	More than 70 countries
Becton Dickinson (BD)	Medical technology and diagnostics	Molecular diagnostics, microbiology, specimen collection	Extensive clinical diagnostics portfolio	Approximately US$21.8 Billion	High	More than 190 countries
Medline Industries	Medical supplies and laboratory products	Infection prevention, diagnostic supplies, laboratory consumables	Large global healthcare distribution network	Approximately US$29 Billion	Moderate	More than 125 countries
Smith & Nephew	Medical technologies and wound care	Infection management, advanced wound care	Strong surgical infection prevention technologies	Approximately US$6.16 Billion	Niche	More than 100 countries
Thermo Fisher Scientific	Life sciences and molecular diagnostics	PCR systems, sequencing, laboratory diagnostics	Industry-leading molecular diagnostics portfolio	Approximately US$43–44 Billion	Very High	Operations in over 180 countries

Leading Trends Shaping the Infectious Disease Diagnostics Market

1. Rapid Growth of Molecular Diagnostics

PCR and real-time PCR technologies continue replacing conventional microbiology because of their superior sensitivity, specificity, and faster turnaround time.

Impact

Faster diagnosis
Improved patient outcomes
Reduced hospitalization
Better outbreak management

2. Expansion of Point-of-Care Testing (POCT)

Healthcare providers increasingly deploy portable diagnostic devices in emergency rooms, pharmacies, clinics, and even homes.

Impact

Immediate treatment decisions
Improved rural healthcare access
Reduced laboratory burden

3. Artificial Intelligence Integration

AI algorithms assist laboratories by interpreting complex diagnostic results and identifying infection patterns.

Impact

Improved diagnostic accuracy
Automated reporting
Faster laboratory workflows

4. Multiplex Diagnostic Panels

Multiplex testing simultaneously identifies multiple respiratory and gastrointestinal pathogens from a single sample.

Impact

Reduced testing costs
Faster clinical decisions
Improved laboratory efficiency

5. Next-Generation Sequencing (NGS)

NGS enables whole-genome sequencing of pathogens and supports epidemiological surveillance.

Impact

Variant identification
Antimicrobial resistance monitoring
Precision infectious disease management

6. Home-Based Diagnostic Testing

Consumer demand for convenient healthcare has accelerated home diagnostic kit adoption.

Impact

Higher patient convenience
Early disease detection
Lower healthcare facility burden

7. Digital Connected Diagnostics

Cloud-enabled diagnostic devices transmit results directly to physicians and public health databases.

Impact

Real-time disease surveillance
Faster reporting
Improved healthcare coordination

8. Automation in Clinical Laboratories

Automation reduces manual laboratory procedures while increasing throughput.

Impact

Lower operational costs
Higher productivity
Improved consistency

Successful Examples of Infectious Disease Diagnostics Around the World

United States

The United States has built one of the world’s most advanced infectious disease diagnostic ecosystems through extensive molecular testing infrastructure. During the COVID-19 pandemic, nationwide PCR capacity expanded dramatically, and hospitals continue to use multiplex respiratory panels for influenza, RSV, SARS-CoV-2, and other respiratory pathogens. The integration of sequencing into surveillance programs has also strengthened detection of emerging variants.

United Kingdom

The United Kingdom has integrated genomic surveillance into its national healthcare system. Large-scale pathogen sequencing supports outbreak investigations, monitors antimicrobial resistance, and informs public health responses.

Germany

Germany has invested heavily in laboratory automation and molecular diagnostics, enabling hospitals and clinical laboratories to deliver rapid infectious disease testing while maintaining high diagnostic accuracy.

India

India has significantly expanded its infectious disease diagnostic capacity through government-supported laboratory networks, tuberculosis elimination initiatives, and increased deployment of molecular diagnostic platforms. Digital health programs and indigenous manufacturing have improved accessibility in urban and rural areas.

China

China has rapidly expanded molecular diagnostic manufacturing capabilities while strengthening infectious disease surveillance infrastructure. High-throughput laboratories support large-scale screening and epidemic response.

Japan

Japan focuses on high-quality molecular diagnostics combined with advanced laboratory automation, enabling rapid diagnosis of respiratory and hospital-acquired infections.

South Korea

South Korea became internationally recognized for its rapid deployment of molecular diagnostic testing during COVID-19. Strong collaboration between government agencies and biotechnology companies enabled rapid commercialization of PCR assays and efficient nationwide testing.

Singapore

Singapore combines digital healthcare infrastructure with advanced laboratory diagnostics, creating one of Asia’s most effective infectious disease surveillance systems.

Global Regional Analysis Including Government Initiatives and Policies

North America

North America represents the largest infectious disease diagnostics market due to advanced healthcare infrastructure, extensive laboratory networks, and high healthcare spending.

Key Market Drivers

Strong biotechnology ecosystem
High adoption of molecular diagnostics
Extensive insurance coverage
Continuous technological innovation

Government Initiatives

Investments by the Centers for Disease Control and Prevention (CDC) in disease surveillance and laboratory modernization.
Support from the Biomedical Advanced Research and Development Authority (BARDA) for pandemic preparedness and rapid diagnostic development.
Ongoing modernization of public health laboratory infrastructure and genomic surveillance programs. Centers for Disease Control and Prevention Biomedical Advanced Research and Development Authority

Europe

Europe continues to be a major contributor due to strong public healthcare systems and coordinated infectious disease monitoring.

Growth Drivers

Universal healthcare access
Advanced diagnostic laboratories
Strong regulatory standards
High investment in research

Government Policies

The European Centre for Disease Prevention and Control coordinates surveillance across EU member states.
The European Health Emergency Preparedness and Response Authority supports preparedness, stockpiling, and innovation for health emergencies.
National governments continue investing in antimicrobial resistance monitoring and laboratory capacity.

Asia-Pacific

Asia-Pacific is expected to register the fastest growth due to rising healthcare investments, increasing infectious disease burden, and expanding domestic diagnostic manufacturing.

Growth Drivers

Large patient population
Rising healthcare expenditure
Increasing laboratory infrastructure
Growing biotechnology investments

Government Initiatives

China

Expansion of national infectious disease surveillance.
Investment in biotechnology innovation and molecular diagnostic manufacturing.

India

The National Centre for Disease Control continues strengthening surveillance and laboratory networks.
Programs targeting tuberculosis elimination and integrated disease surveillance have increased access to molecular diagnostics.

Japan

Continued government support for precision medicine, laboratory automation, and infectious disease preparedness.

South Korea

National investments in biotechnology R&D and rapid commercialization pathways for diagnostic innovations have strengthened preparedness for emerging infectious diseases.

Latin America

Latin America is experiencing increasing adoption of infectious disease diagnostics due to the persistent burden of mosquito-borne and respiratory diseases.

Market Drivers

Expanding healthcare access
Rising awareness
Government disease surveillance programs
International healthcare funding

Government Policies

Countries including Brazil, Mexico, and Chile have strengthened laboratory capacity for dengue, Zika, chikungunya, influenza, and antimicrobial resistance monitoring while expanding public health surveillance networks.

Middle East & Africa

The Middle East & Africa region presents substantial growth opportunities due to increasing investments in healthcare modernization and disease control.

Growth Drivers

Expanding healthcare infrastructure
Rising prevalence of infectious diseases
International funding support
Growing diagnostic laboratory networks

Government Initiatives

Governments across the Gulf Cooperation Council (GCC) countries continue investing in laboratory modernization, digital healthcare systems, and infectious disease preparedness. Several African countries are strengthening surveillance programs with support from international organizations to improve early detection of tuberculosis, HIV, malaria, and emerging infectious diseases.

Future Outlook

The infectious disease diagnostics market is expected to remain one of the fastest-evolving segments of healthcare over the coming decade. Advances in molecular biology, artificial intelligence, digital health integration, portable diagnostics, multiplex assays, and genomic sequencing will continue to transform how infectious diseases are detected and managed. As governments prioritize pandemic preparedness, antimicrobial resistance monitoring, and equitable access to diagnostics, market participants that combine innovation, automation, and scalable manufacturing will be well positioned to capitalize on growing global demand.